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ABSTRACT 
Hyperphosphaturic Mesenchymal Tumor (HMT) is a very rare benign tumor of the soft tissue or bone which produces tumor 
induced osteomalacia, also called as oncogenic osteomalacia. This activity can only be stopped by the surgical removal of the 
tumor. We present a 23 years old man who presented with long standing bony pains without any relief by a variety of 
medications. The clue to the diagnosis was taken from pelvis skiagram, Magnetic Resonance Imaging (MRI) of the body, PET 
scan and the blood chemistry.  
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yperphosphaturic Mesenchymal Tumor (HMT) 
was first described in 1947 by Mc Cance and 
Prader et al in 1959 further discovered its 
association with metabolic disorder [1]. HMT is a rare 
benign tumor of soft tissue or bone which produces tumor 
induced osteomalacia, or oncogenic osteomalacia. This 
paraneoplastic syndrome acts by secreting fibroblast 
growth factor-23 (FGF-23). These act by inhibiting renal 
tubular reabsorption of phosphate along with conversion of 
25 hydroxyvitamin D3 to dihydroxy vitamin D3, resulting 
in phophaturia and hypophostemia. These tumors are often 
of the mesenchymal in origin.  
There is paucity of literature about the detailed 
pathophysiology of these tumors because of their rarity 
[2]. Children are less affected by tumor induced 
osteomalacia as compared to the elderly age group. The 
pediatric patients are usually affected by genetically linked 
syndromes and diseases.  
 
CASE REPORT 
23 years old male presented with generalized bony pains 
of five year duration unrelieved with medication. He had 
progressive difficulty in walking and limping. He was 
treated by multiple physicians without much improvement; 
therefore, he was referred to us for further management. 
There was no history of trauma, fever or surgery. On 
examination, he was afebrile, conscious with stable vital 
signs. Tenderness was present over left hip joint. His 
systemic examination showed no abnormality. 
Plain X-ray pelvis AP view had shown mildly 
decreased bone density with loser’s zone. The pelvis has 
shown triradiate configuration with transcervical fracture 
of left femoral neck (Figure 1). Blood chemistry has 
shown normal calcium levels with decreased serum 
phosphate (2.9 mg/dL), increased serum alkaline 
phosphatase (1200 IU/L) and normal parathyroid levels. 
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Renal and liver function tests were normal. MRI shows 
well defined soft tissue lesion adjacent to the left sacroiliac 
joint measuring 17x11x14 mm. The lesion was 
hypointense on T1W (Figure 2a) and shows intense 
homogenous post contrast enhancement (Figure 2b). 
Lesion showed hyperintensity on T2W (Figure 2c) and 
STIR images (Figure 3).   
 
Figure 1 - X ray Pelvis AP view shows osteomalacia related 
changes along with looser’s zone and trans-cervical fracture 
of the neck of the left femur (white arrow).The pelvis is of 
triradiate configuration (white cross). 
 
Figure 2 (a) - Non contrast T1W fat sat image shows a mixed 
intensity well defined lesion present on the medial aspect of 
the left sacroiliac joint (black arrow). (b) - Contrast T1W 
image shows the intense enhancement (thin black arrow) of 
the lesion. (c) - T2W fat sat axial section shows hyperintense 
(black arrow) lesion at the same location. 
 
Figure 3 - STIR Coronal image shows the hyperintense well 
defined lesion (black arrow). 
Diagnosis of tumor induced osteomalacia was made 
and Positron Emission Tomography (PET) (DOTA-NOC 
or 1,4,7,10-tetraazacyclododecane-1,1,7,10-tetraacetic 
acid)-1NaI(3)-octreotide) scan was performed which 
showed increased uptake adjacent to the left sacroiliac 
joint. Plasma fibroblast growth factor-23 level was 
increased to 282.9 RU/mL (normal - 180 RU/mL). The 
complete tumor was surgically resected from the pelvic 
region. The tumor was totally separated out from the 
adjoining areas. The post operative period was uneventful. 
Histopathologic examination (HPE) of the specimen 
confirmed the diagnosis which showed benign 
mesenchymal tumor rich in blood vessels. The tumor is 
arranged predominantly around the thin walled small 
vascular channels and interspersed thick walled medium 
sized vessels with medial hypertrophy. The tumor cells are 
bland appearing and show oval to plump nucleus with mild 
degree of pleomorphism, fine chromatin and moderate 
amount of cytoplasm. At places there is new bone. The 
blood parameters returned to normal in six months after 
the resection and there was no further deterioration of the 
symptoms. 
DISCUSSION 
Hyperphosphaturic Mesenchymal Tumors cause 
debilitating osteomalcia with resultant long standing bone 
pains and pathological fractures. The diagnosis can be 
confirmed first by blood chemistry and then by 
radionuclide studies or imaging modalities. Blood tests 
often reveal low phosphate levels, elevated alkaline 
phosphatase and low 1,25 dihydroxy vitamin D3 levels. In 
our case, the long standing bony pains was the main 
feature and also resulted in transcervical fracture of the left 
femoral neck because of underlying osteomalacia. Clue 
can be obtained from increased urine phosphate excretion.  
Fibroblast Growth Factor (FGF) 23, secreted by 
mesenchymal tumors, is the factor responsible for all the 
physiological changes seen in HMT [3]. It restricts the 
reabsorption of phosphate from the proximal renal tubules 
resulting in high urinary phosphate levels [4]. Plasma FGF 
23 was markedly raised in our case. The diagnosis can be 
missed if the increase in urine phosphate got unnoticed as 
sometimes this may be the only clue to suspect the tumor 
[5]. Other similar condition like familial 
hypophosphatemic rickets and Fanconi syndrome can be 
ruled out by the negative family history.  
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Radiological modalities like plain radiography, MRI 
and PET scan help in diagnosing these types of rare 
tumors. The localization of small tumors is easy by 
multiplanar and multisectional imaging by MRI as this has 
high specificity of tissue characterization. Management 
can be done by surgical resection of the underlying 
tumour, which usually leads to immediate cure [7]. The 
patients are treated with 1-3 microgram /day Calcitriol and 
1-4 g/day of Phosphorus in divided doses after the surgery 
till symptoms subsides. The correct and timely diagnosis 
of the pathology can prevent many complications of the 
disease. 
 CONCLUSION 
The cause of suspicious osteomalacia must be investigated 
by biochemical, radionucleotide and imaging studies. 
Radiological Imaging modalities like X-ray, PET and MRI 
are of great importance to locate the tumors in the cases of 
tumor induced osteomalacia. 
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